Jump Financial LLC lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 644.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,815 shares of the company's stock after acquiring an additional 139,226 shares during the quarter. Jump Financial LLC owned 0.16% of Trevi Therapeutics worth $1,012,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the company. Wellington Management Group LLP purchased a new stake in shares of Trevi Therapeutics during the 1st quarter worth approximately $802,000. Raymond James Financial Inc. lifted its stake in Trevi Therapeutics by 4,144.8% in the 1st quarter. Raymond James Financial Inc. now owns 509,379 shares of the company's stock valued at $3,204,000 after buying an additional 497,379 shares in the last quarter. American Century Companies Inc. lifted its stake in Trevi Therapeutics by 2.1% in the 1st quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock valued at $502,000 after buying an additional 1,653 shares in the last quarter. Tejara Capital Ltd lifted its stake in Trevi Therapeutics by 16.8% in the 1st quarter. Tejara Capital Ltd now owns 179,516 shares of the company's stock valued at $1,129,000 after buying an additional 25,777 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in Trevi Therapeutics in the 1st quarter valued at approximately $260,000. Hedge funds and other institutional investors own 95.76% of the company's stock.
Wall Street Analyst Weigh In
TRVI has been the topic of a number of recent research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Morgan Stanley initiated coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They issued an "overweight" rating and a $18.00 target price on the stock. Raymond James Financial reduced their target price on Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC reduced their target price on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, HC Wainwright started coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $20.11.
Get Our Latest Stock Report on Trevi Therapeutics
Trevi Therapeutics Price Performance
TRVI traded up $0.08 during trading on Thursday, hitting $7.23. The company's stock had a trading volume of 1,953,144 shares, compared to its average volume of 1,901,081. The firm's 50 day moving average price is $7.04 and its 200-day moving average price is $6.36. The stock has a market cap of $880.47 million, a PE ratio of -17.21 and a beta of 0.71. Trevi Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $8.78.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.
About Trevi Therapeutics
(
Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Articles

Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.